Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA Investigates Safety Concerns Surrounding Takeda's Rare Disease Drug Adzynma

FDA Investigates Safety Concerns Surrounding Takeda's Rare Disease Drug Adzynma

The U.S. Food and Drug Administration (FDA) has launched an investigation into Takeda Pharmaceutical's enzyme replacement therapy, Adzynma, following reports of serious adverse events, including a pediatric patient death. The probe centers on the development of neutralizing antibodies in patients treated with the drug, which was approved in 2023 for congenital thrombotic thrombocytopenic purpura (cTTP).

NoahAI News11/25/2025
Novo Nordisk Faces Setback in Alzheimer's Trial, Market Reacts Sharply

Novo Nordisk Faces Setback in Alzheimer's Trial, Market Reacts Sharply

Novo Nordisk, the Danish pharmaceutical giant, has encountered a significant setback in its pursuit of an Alzheimer's disease treatment, leading to a notable market reaction and raising questions about the company's future prospects in the highly competitive pharmaceutical landscape.

NoahAI News11/25/2025
Insulet Unveils Ambitious Plans for Next-Generation Diabetes Devices

Insulet Unveils Ambitious Plans for Next-Generation Diabetes Devices

Insulet, a leading manufacturer of insulin patch-pumps, has announced its strategic roadmap for the coming years, including plans for new devices aimed at revolutionizing diabetes management. The company's ambitious agenda includes updates to its current Omnipod 5 system, the development of a next-generation Omnipod 6 device, and a groundbreaking fully closed-loop system for Type 2 diabetes patients.

NoahAI News11/25/2025
Biogen Expands Immunology Portfolio with $50M Deal, Versant Launches Macrocyclic Peptide Startup

Biogen Expands Immunology Portfolio with $50M Deal, Versant Launches Macrocyclic Peptide Startup

Biogen has entered into a significant research collaboration with newly launched biotech Dayra Therapeutics, marking a strategic expansion of its immunology portfolio. The deal, announced on November 24, 2025, involves a $50 million upfront payment from Biogen and showcases the growing interest in oral macrocyclic peptides as a promising therapeutic approach.

NoahAI News11/25/2025
Health Tech Venture Capital Rebounds in 2025, Driven by AI Innovations

Health Tech Venture Capital Rebounds in 2025, Driven by AI Innovations

Venture capital funding for healthcare technology startups has shown a strong recovery in 2025, with investment through the third quarter already surpassing last year's total, according to a recent report by PitchBook. The resurgence is largely attributed to the growing interest in artificial intelligence (AI) applications within the healthcare sector.

NoahAI News11/25/2025
Merck's ADC-Keytruda Combo Shows Promise in First-Line Lung Cancer Treatment

Merck's ADC-Keytruda Combo Shows Promise in First-Line Lung Cancer Treatment

Merck & Co. and its partner Kelun-Biotech have reported a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC), as their antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) combined with Keytruda demonstrated superior efficacy in a phase 3 trial.

NoahAI News11/25/2025
AI-Powered Women's Health Startup Millie Launches Maia Agent, Prepares for AI-Forward Future

AI-Powered Women's Health Startup Millie Launches Maia Agent, Prepares for AI-Forward Future

Women's health startup Millie has taken a significant step towards revolutionizing maternal care with the launch of its AI agent, Maia. This development comes as part of the company's broader strategy to integrate artificial intelligence into its healthcare services, positioning itself at the forefront of the AI revolution in women's health.

NoahAI News11/25/2025
Sarepta's RNA Therapy for DM1 Progresses, Triggering $200M Milestone Payment to Arrowhead

Sarepta's RNA Therapy for DM1 Progresses, Triggering $200M Milestone Payment to Arrowhead

Sarepta Therapeutics has announced positive developments in its phase 1/2 trial for SRP-1003, a small interfering RNA (siRNA) therapeutic targeting type 1 myotonic dystrophy (DM1). The progress has resulted in a significant milestone payment to partner Arrowhead Pharmaceuticals and has been met with enthusiasm from industry analysts.

NoahAI News11/25/2025
Optum Rx Expands Prior Authorization Reduction Initiatives, Surpassing Initial Goals

Optum Rx Expands Prior Authorization Reduction Initiatives, Surpassing Initial Goals

Optum Rx, the pharmacy benefit management arm of UnitedHealth Group, has announced significant expansions to its prior authorization reduction initiatives, exceeding its original targets set earlier this year. The company will implement these changes starting January 1, 2026, marking a substantial shift in how medication approvals are handled for millions of patients.

NoahAI News11/25/2025
J&J MedTech Expands Stroke R&D Programs in Ireland, Reinforcing Global Neurovascular Innovation

J&J MedTech Expands Stroke R&D Programs in Ireland, Reinforcing Global Neurovascular Innovation

Johnson & Johnson MedTech is bolstering its stroke-focused research and development efforts in Ireland, marking a significant expansion of its neurovascular capabilities in the region. This move builds upon previous investments and follows the completion of a new innovation center in Galway earlier this year.

NoahAI News11/25/2025
Bayer's Asundexian Shows Promise in Phase III Stroke Prevention Study

Bayer's Asundexian Shows Promise in Phase III Stroke Prevention Study

Bayer's investigational Factor XIa inhibitor, asundexian, has demonstrated significant efficacy in stroke prevention, according to recent Phase III clinical trial results. This development marks a potential turnaround for the drug, which previously faced setbacks in atrial fibrillation studies.

NoahAI News11/24/2025
J&J's Alzheimer's Ambitions Suffer Setback as Anti-Tau Antibody Fails Phase 2 Trial

J&J's Alzheimer's Ambitions Suffer Setback as Anti-Tau Antibody Fails Phase 2 Trial

Johnson & Johnson's aspirations to develop a blockbuster Alzheimer's disease treatment have been dealt a significant blow following the failure of its anti-tau antibody, posdinemab, in a phase 2 clinical trial. The company announced that the drug failed to significantly slow clinical decline in patients with early Alzheimer's, leading to the termination of the study.

NoahAI News11/24/2025
«1...131415...67»